Difference between revisions of "Team:Northwestern"

 
(87 intermediate revisions by 4 users not shown)
Line 16: Line 16:
 
     <title>Home</title>
 
     <title>Home</title>
 
     <!-- Bootstrap -->
 
     <!-- Bootstrap -->
−
        <script type="text/javascript" src="https://2016.igem.org/Team:Northwestern/libraries/jquery?action=raw&ctype=text/javascript"></script>
+
<link rel="stylesheet" type="text/css" href="https://2017.igem.org/Template:Northwestern/CSS?action=raw&ctype=text/css" />
−
        <script type="text/javascript" src="https://2016.igem.org/Team:Northwestern/libraries/bootstrap?action=raw&ctype=text/javascript"></script>
+
  
 
<style>
 
<style>
Line 67: Line 66:
 
     <span style="color:#4C177D;" class="w3-xxxlarge glyphicon glyphicon-chevron-down">
 
     <span style="color:#4C177D;" class="w3-xxxlarge glyphicon glyphicon-chevron-down">
 
     </span>
 
     </span>
 +
 +
 +
 +
 +
 
   </button>
 
   </button>
 
</div>
 
</div>
Line 73: Line 77:
  
 
<div class="bgimg-2 w3-display-container" id="first">
 
<div class="bgimg-2 w3-display-container" id="first">
−
   <div style="padding: 10%;">
+
   <div style="padding: 5% 10%;">
−
   <h3 style="color:white" class="w3-center w3-padding-large">Designing pathways for integrating functional Cas9 protein into OMVs </h3><br>  
+
   <h3 style="color:white" class="w3-center w3-padding-large"><br><br>Engineering pathways for integrating functional Cas9 protein into OMVs </h3><br>  
 
<p style="padding-right: 10%; padding-left:10%; font-size:14px; color:white;" class="big">  Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.<br><br>
 
<p style="padding-right: 10%; padding-left:10%; font-size:14px; color:white;" class="big">  Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.<br><br>
 
</p>
 
</p>
  
−
   <ul class="ch-grid" style="margin-left:0px;">
+
   <ul class="ch-grid" height="50%" style=padding:0;">
 
     <li>
 
     <li>
 
       <div class="ch-item ch-img-2">
 
       <div class="ch-item ch-img-2">
Line 93: Line 97:
 
           <h3 class="ch-bubble">Project description</h3>
 
           <h3 class="ch-bubble">Project description</h3>
 
           <p class="ch-bubble">Outer Membrane Vesicles<br>
 
           <p class="ch-bubble">Outer Membrane Vesicles<br>
−
           <a class="ch-bubble" href="https://2016.igem.org/Team:Northwestern/Description">LEARN MORE</a></p>
+
           <a class="ch-bubble" href="https://2017.igem.org/Team:Northwestern/project">LEARN MORE</a></p>
 
         </div>
 
         </div>
 
       </div>
 
       </div>
Line 100: Line 104:
 
       <div class="ch-item ch-img-3">
 
       <div class="ch-item ch-img-3">
 
         <div class="ch-info">
 
         <div class="ch-info">
−
           <h3 class="ch-bubble">Our Results</h3>
+
           <h3 class="ch-bubble">Parts</h3>
−
           <p class="ch-bubble">Cas9 Encapsulation<br>
+
           <p class="ch-bubble">Cas9 fusion proteins<br>
−
             <a class="ch-bubble" href="https://2016.igem.org/Team:Northwestern/Results">LEARN MORE</a></p>
+
             <a class="ch-bubble" href="https://2017.igem.org/Team:Northwestern/Parts">LEARN MORE</a></p>
−
        </div>
+
          </div>
 
       </div>
 
       </div>
 
     </li>
 
     </li>
Line 111: Line 115:
 
</div>
 
</div>
 
<div style="z-index:1 !important;" class="w3-display-bottommiddle">
 
<div style="z-index:1 !important;" class="w3-display-bottommiddle">
−
<button style="position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small" onclick="scrollWin2()">
+
<button height="80%" width="auto" style="position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small w3-hide-medium" onclick="scrollWin2()">
 
     <span style="color:white;" class="w3-xxxlarge glyphicon glyphicon-chevron-down">
 
     <span style="color:white;" class="w3-xxxlarge glyphicon glyphicon-chevron-down">
 
     </span>
 
     </span>
Line 117: Line 121:
 
</div>
 
</div>
 
</div>
 
</div>
−
 
  
  
  
 
<div class="bgimg-3 w3-display-container" id="second">
 
<div class="bgimg-3 w3-display-container" id="second">
−
<div style="padding: 10%;">
+
<div style="padding: 5% 10%;">
−
<h3 style="black;" class="w3-center w3-padding-large">Project significance</h3><br>  
+
<h3 style="black;" class="w3-center w3-padding-large"><br><br>Project significance</h3><br>  
−
<p style="padding-bottom:0; padding-right: 10%; padding-left:10%; black; font-size:14px;" class="big"> OMVs are a promising delivery system because of their easy manipulation and broad range of sizes. Our team is working on developing ways to direct the CRISPR system into these export vesicles. To do this, we engineer genetic components that target the Cas9 protein and its guide RNA into a portion of the bacterial membrane called the periplasm. From there, the CRISPR system can be taken up into the OMVs to be delivered to other cells. Upon delivery, the guide RNA will direct the protein to cut out the antibiotic resistance gene. With the gene deleted, the bacteria will not be able to resist antibiotics, making treatments much more effective. NEED TO CHANGE THIS PARAGRAPH. </p>
+
<p style="padding-bottom:0; padding-right: 10%; padding-left:10%; black; font-size:14px;" class="big"> VesiCure aims to create a therapeutic delivery system for CRISPR gene-editing technology using bacterial outer-membrane vesicles (OMVs). We hope to be able to utilize this delivery system to target the antibiotic resistant genes in bacteria, thereby allowing antibiotic treatments to be effective by eliminating the adaptive ability of bacterial resistance. <b>By genetically altering the resistant bacteria, this treatment would help combat the problem of antibiotic resistance directly from the source</b>.<br><br> </p>
 +
 
 +
<figure>
 +
<br><br><br>
 +
<center><img src="https://static.igem.org/mediawiki/2017/c/c0/T--Northwestern--GlobePractices.png" width="350px" border="0">
 +
</center></figure>
 +
 
 +
 
 +
 
 +
 
  
−
<center><img style="display: block; padding:0;" src = "https://static.igem.org/mediawiki/2017/4/4e/T--Northwestern--schematic2.png" width="50%"></center>
 
 
<div style="z-index:1 !important;" class="w3-display-bottommiddle">
 
<div style="z-index:1 !important;" class="w3-display-bottommiddle">
−
<button style="margin:0; padding:0; position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small" onclick="scrollWin3()">
+
<button style="margin:0; padding:0; position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small w3-hide-medium" onclick="scrollWin3()">
 
     <span style="color:black;" class="w3-xxxlarge glyphicon glyphicon-chevron-down">
 
     <span style="color:black;" class="w3-xxxlarge glyphicon glyphicon-chevron-down">
 
     </span>
 
     </span>
Line 136: Line 147:
 
</div>
 
</div>
  
−
<div style="padding:10%;" class="bgimg-4 w3-display-container" id="third">
+
 
−
  <div>
+
 
−
</div>
+
−
<div style="z-index:1 !important;" class="w3-display-bottommiddle">
+
−
<button style="position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small" onclick="scrollWin4()">
+
−
    <span style="color:black;" class="w3-xxxlarge glyphicon glyphicon-chevron-down">
+
−
    </span>
+
−
  </button>
+
−
</div>
+
−
</div>
+
  
 
<div class="w3-display-container">
 
<div class="w3-display-container">
Line 152: Line 155:
 
</div>
 
</div>
 
<div class="w3-center container">  
 
<div class="w3-center container">  
−
<span class="w3-center"> <video class="w3-center" controls><source src= "https://static.igem.org/mediawiki/2016/4/48/T--Northwestern--project_video.mp4" type="video/mp4" type="video/mp4"></video> </span>  
+
<span class="w3-center"> <video class="w3-center" controls><source src= "https://static.igem.org/mediawiki/2017/6/60/T--Northwestern--videofast.mp4" type="video/mp4" type="video/mp4"></video> </span>  
 
</div>  
 
</div>  
 
</div>
 
</div>
Line 172: Line 175:
 
   </div>
 
   </div>
 
</div>
 
</div>
 +
<br>
 +
<br>
  
 
</body>
 
</body>
 
</html>
 
</html>
 
{{Northwestern_Page_Foot_temp}}
 
{{Northwestern_Page_Foot_temp}}

Latest revision as of 17:09, 20 November 2017

Northwestern Template Northwestern Template

Overview Silver Gold Collaborations Engagement
Overview
Experiments Modeling Results Notebook Safety Interlab
Description Design Medal Criteria
About Us Attributions

Home



Engineering pathways for integrating functional Cas9 protein into OMVs


Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.



Project significance


VesiCure aims to create a therapeutic delivery system for CRISPR gene-editing technology using bacterial outer-membrane vesicles (OMVs). We hope to be able to utilize this delivery system to target the antibiotic resistant genes in bacteria, thereby allowing antibiotic treatments to be effective by eliminating the adaptive ability of bacterial resistance. By genetically altering the resistant bacteria, this treatment would help combat the problem of antibiotic resistance directly from the source.




Check out the video below to learn more about our project!